Eli Lilly’s Kisunla approved by FDA for Alzheimer’s treatment
July 3, 2024Medical Communications Alzheimer's, Eli Lilly, Kisunla, Neurology
Eli Lilly has announced that the US Food and Drug Administration (FDA) has approved Kisunla (donanemab-azbt, 350mg/20ml once-monthly injection for …
Arcturus Therapeutics provides update on OTC deficiency and CF programmes
July 2, 2024Research and Development Arcturus Therapeutics, OTC, Pharmacy, clinical trials, cystic fibrosis
Arcturus Therapeutics has announced mid-year updates for ARCT-810, an investigational mRNA therapeutic to treat ornithine transcarbamylase (OTC) deficiency, and ARCT-032, …
NeuroSense shares update from ALS treatment trial
July 2, 2024Research and Development NeuroSense, Neurology, als, clinical trial
NeuroSense has announced new statistically significant results from the 12-month analysis of its PARADIGM phase 2b study which assessed PrimeC …
Sanofi shares results from phase 2 trial for frexalimab in MS treatment
July 1, 2024Research and Development MS, Neurology, Sanofi, multiple sclerosis
Sanofi has announced new phase 2 trial data for its CD40L monoclonal antibody, frexalimab, for the treatment of patients with …
EMA accepts AstraZeneca’s regulatory submission for sipavibart for COVID-19 prevention
July 1, 2024Research and Development COVID-19, EMA, Infections and infestations, coronavirus
AstraZeneca has announced that the European Medicines Agency (EMA) has accepted its Marketing Authorisation Application (MAA) for sipavibart under the …
Eisai and Biogen’s Leqembi launched for Alzheimer’s treatment in China
June 28, 2024Business Services Alzheimers, Biogen, Eisai, Leqembi, Neurology, lecanemab
Eisai and Biogen have announced that Leqembi (lecanemab) has been launched in China as a treatment for mild cognitive impairment …
AbbVie’s Tepkinly gains positive CHMP opinion for follicular lymphoma treatment
June 28, 2024Medical Communications AbbVie, CHMP, EMA, Oncology, follicular lymphoma
AbbVie has announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has granted a …
IDEAYA Biosciences announces first-patient-in for phase 1 clinical trial evaluating IDE397 and Trodelvy combination in MTAP-deletion bladder cancer
June 27, 2024Research and Development IDEAYA Biosciences, Oncology, bladder cancer, clinical trials, oncology
Precision medicine oncology company IDEAYA Biosciences has announced that the first patient in the IDEAYA-sponsored phase 1 trial has been …
Immunotherapy created at Roswell Park Comprehensive Cancer Center given expanded ODD by FDA
June 27, 2024Research and Development MimiVax, Oncology, Orphan Drug Designation, Roswell Park Comprehensive Cancer Center, immunotherapies, oncology
The US Food and Drug Administration (FDA) has granted an expanded Orphan Drug Designation (ODD) for brain cancer immunotherapy SurVaxM, …
Abcuro completes enrolment for phase 2/3 IBM treatment trial
June 26, 2024Research and Development Abcuro, Musculo-skeletal disorder, ibm, inclusion body myositis, ulviprubart
Abcuro has announced that it has completed the enrolment for its registrational phase 2/3 MUSCLE clinical trial, which aims to …
AskBio initiates phase 2 Parkinson’s trial recruitment
June 26, 2024Research and Development AskBio, Neurology, Parkinson's disease, clinical trial
Asklepios BioPharmaceutical (AskBio), a subsidiary of Bayer, has announced that it has initiated the recruitment for its phase 2 REGENERATE-PD …
AstraZeneca’s Tagrisso approved in Japan for lung cancer treatment
June 25, 2024Medical Communications AstraZeneca, Oncology, Tagrisso, chemotherapy, lung cancer
AstraZeneca has announced that Tagrisso (osimertinib) in combination with pemetrexed and platinum-based chemotherapy has been approved in Japan for the …
ILiAD Biotechnologies announces collaboration with Emmes Group on phase 3 pertussis vaccine trial
June 25, 2024Research and Development Emmes Group, ILiAD Biotechnologies, Infections and infestations, Vaccine, whooping cough
ILiAD Biotechnologies has announced that it has selected Emmes Group to conduct the upcoming phase 3 trials of its lead …
GSK’s Jemperli accepted for review by EMA for endometrial cancer treatment
June 24, 2024Medical Communications EMA, GSK, Jemperli, Oncology, endometrial cancer
GSK has announced that the European Medicines Agency (EMA) has accepted the application to expand the use of Jemperli (dostarlimab) …
Vertex shares results from phase 1/2 trial of type 1 diabetes treatment
June 24, 2024Research and Development Diabetes, Vertex pharmaceuticals, clinical trial, diabetes
Vertex Pharmaceuticals has announced new data from its phase 1/2 clinical trial of VX-880, an investigational stem cell-derived, fully differentiated …
Gilead shares phase 3 results from HIV prevention trial
June 21, 2024Research and Development Gilead, HIV, Infections and infestations, clinical trial
Gilead Sciences has announced results from an interim analysis of its pivotal, phase 3 PURPOSE 1 trial, which assessed the …
Sarepta Therapeutics gains expanded FDA approval for DMD treatment
June 21, 2024Medical Communications DMD, Musculo-skeletal disorder, Sarepta Therapeutics
Sarepta Therapeutics has announced that the US Food and Drug Administration (FDA) has approved an expansion to the labelled indication …
FDA approves AbbVie’s Skyrizi for UC treatment
June 20, 2024Medical Communications AbbVie, FDA, Gastrointestinal tract, UC, ibd
AbbVie has announced that the US Food and Drug Administration (FDA) has approved Skyrizi (risankizumab-rzaa) for the treatment of adult …
Takeda shares data from phase 3 trial of CIPD treatment
June 20, 2024Research and Development CIDP, Hyqvia, Neurology, Takeda, clinical trial
Takeda has announced data from the phase 3 ADVANCE-CIDP 3 trial, which assessed the safety and efficacy of Hyqvia (Immune …
EC grants marketing authorisation to Sobi’s Altuvoct for haemophilia A treatment
June 19, 2024Medical Communications Altuvoct, EC, EMA, Haematology, haemophilia a, sobi
Sobi has announced that the European Commission (EC) has granted marketing authorisation for Altuvoct (efanesoctocog alfa) for the treatment and …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
